Gyongyi Szabo, MD, PhD
Associate Dean for Clinical and Translational Science
Director, MD/PhD Program
Vice Chair for Research
Department of Medicine University of Massachusetts Medical School
Dr. Gyongyi Szabo is the Worcester Foundation for Biomedical Research Endowed Chair, Associate Vice Provost for Inter Professional Education and Vice Chair in the Department of Medicine at the University of Massachusetts Medical School, Worcester, MA. She is a physician scientist with active translational and clinical research studies in liver diseases. Dr. Szabo is an international authority in liver inflammation and immunity. Her research focuses on cellular and molecular mechanisms of inflammation in alcoholic and non-alcoholic liver diseases whit the goal to identify and test novel therapeutic approaches for steatohepatitis that could be brought to the clinic. She is member of the Hungarian Academy of Sciences and serves on advisory boards of several academic institutions and pharmaceutic companies. She is Immediate Past President of the American Association of the Study of Liver Diseases, the largest professional society in liver diseases and the inaugural Editor-in Chief of Hepatology Communications.
Hari S. Conjeevaram, MD Professor
Division of Gastroenterology
University of Michigan Medical Center, Ann Arbor
Dr. Hari Conjeevaram is Director of the Fatty Liver Disease Clinic and professor at the University of Michigan Medical Center. He received his medical degree from Madras University in India and completed his residency and fellowship at Metro Health Medical Center in Cleveland, Ohio. Dr. Conjeevaram’s interests include viral hepatitis B and C, nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH), acute and chronic liver diseases, and liver transplantation.
Ariel E. Feldstein, MD
Professor of Pediatrics
Chief, Division of Pediatric Gastroenterology,
Hepatology, and Nutrition University of California San Diego
Dr. Ariel Feldstein is Chief of the Gastroenterology, Hepatology & Nutrition Division at Rady Children's Hospital-San Diego and a professor of pediatrics at UC San Diego School of Medicine. After graduating from the Universidad de Buenos Aires Medical School and completing a postdoctoral program in physiology at the Mayo Clinic, Dr. Feldstein went on to become the director of research for the Pediatric Institute at the Cleveland Clinic before moving to San Diego in 2011. Dr. Feldstein oversees one of the largest pediatric gastroenterology divisions in the country. He is a renowned pediatric hepatologist who pioneered the development of non-invasive blood tests to monitor liver damage. His lab at UCSD combines significant basic and translational research expertise focusing on mechanisms of cell death and sterile inflammation during acute and chronic liver injury in particular non-alcoholic steatohepatitis.
Kris V. Kowdley MD
Director of the Liver Care Network and Organ Care Research
Swedish Medical Center, Seattle, Washington
Dr. Kris Kowdley is Director of the Liver Care Network and Organ Care Research at the Swedish Medical Center in Seattle, WA. He received his BS in Biology and Anthropology as a member of the Dean's List at Columbia University, and his medical degree from Mount Sinai School of Medicine. He completed his internship and residency at Oregon Health Science University and a Fellowship in Gastroenterology and Hepatology at Tufts University School of Medicine. He is internationally recognized as a clinician, educator and researcher in the area of liver disease and is the author of over 400 articles, book chapters, reviews and commentaries. Dr. Kowdley has extensive experience in clinical trials in all areas of liver disease, ranging from hepatitis C, cholestatic liver disease, nonalcoholic steatohepatitis and hepatitis B. His lab is focused on the role of iron as a co-factor in many liver diseases, ranging from hepatitis C, hemochromatosis and nonalcoholic steatohepatitis (NASH). He has developed murine models for NASH and is currently exploring the contribution of hepatic iron deposition on the severity of NASH.
Pranoti Mandrekar, PhD
Department of Medicine
Co-Director,Translational Science program
Graduate School of Biomedical Sciences
University of Massachusetts Medical School
Dr. Pranoti Mandrekar is Professor in the Department of Medicine and Co-Director of the Translational Science program at the Graduate School of Biomedical Sciences at University of Massachusetts Medical School. She received both her MS in Biochemistry and her PhD in Cancer Biology at the University of Mumbai in Mumbai, India. Dr. Mandrekar’s research focuses on mechanisms of activation and signaling pathways in innate immune cells; cytokines and chemokines in liver injury, fibrosis and cancer; translational and pre-clinical research in liver diseases; proteostasis, chaperones and cellular stress response pathways in metabolism; toll-like receptor pathways and inflammation in steatohepatitis; host defense and inflammation.
Ekihiro Seki MD, PhD
Division of Gastroenterology, Department of Medicine
Cedars-Sinai Medical Center, Los Angeles
Dr. Ekihiro Seki’s expertise lies in the field of liver immunology, and basic and translational gastroenterology and hepatology research. The research team has expertise in using genetically modified animals and isolation of primary cultured liver cells including hepatocytes, Kupffer cells, and hepatic stellate cells. Dr. Seki was trained as a GI-hepatobiliary surgery in Japan. After his clinical training, Dr. Seki started his research career studying liver immunology including Toll-like receptor signaling and inflammasome activation. In his postdoctoral training at Columbia University, he studied the role of TLR4 signaling in liver fibrosis. After his first faculty appointment at UC San Diego, Dr. Seki is currently conducting his basic and translational research focusing on matrix-mediated liver fibrosis, alcoholic and non-alcoholic fatty liver disease, and liver malignancy at Cedars-Sinai Medical Center.
Norah A. Terrault, MD, MPH, FAASLD
University of California, San Francisco
San Francisco, CA
READ FROM THE AASLD:
A Message from the AASLD President
United States Travel Restrictions